Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03928041 · ClinicalTrials.gov registry record · NA

A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages in the Lumbar Spine

A NA study of Degenerative Disc Disease Lumbar and Spondylolisthesis, Grade 1, sponsored by Invibio.

Completed
Registry status
NA
Development phase
22
Enrollment target
2
Study locations

NCT03928041 is a NA study of Degenerative Disc Disease Lumbar and Spondylolisthesis, Grade 1 that has completed, run by Invibio. The registered enrollment target is 22 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03928041, a NA study of Degenerative Disc Disease Lumbar and Spondylolisthesis, Grade 1, has completed, sponsored by Invibio.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo interbody spinal fusion using the EVOS Lumbar Interbody System.

Interventions

  • DEVICE Device: EVOS Lumbar Interbody System (EVOS-HA)

Study Locations (2)

North Carolina

  • OrthoCarolina Research Institute - Charlotte

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-06-27
Est. Completion 2023-09-25
Phase NA

Sponsor

Invibio

4 total trials

What the Registry Record Tells You About NCT03928041

The ClinicalTrials.gov registry entry for NCT03928041 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invibio, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Degenerative Disc Disease Lumbar appearing as the primary indexed condition, and to 1 intervention - of which Device: EVOS Lumbar Interbody System (EVOS-HA) is the first listed.

NCT03928041 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03928041 about?

NCT03928041 is a clinical study titled "A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced Interbody Cages in the Lumbar Spine". The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo interbody spinal fusion using the EVOS Lumbar Interbody System.

What is the current status of trial NCT03928041?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2019-06-27. Estimated completion is 2023-09-25.

What conditions does trial NCT03928041 study?

This clinical trial studies the following conditions: Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1.

What interventions are being tested in trial NCT03928041?

The interventions under investigation include: Device: EVOS Lumbar Interbody System (EVOS-HA) (DEVICE).

Who is sponsoring clinical trial NCT03928041?

This trial is sponsored by Invibio, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03928041 being conducted?

This trial has 2 study locations across North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Degenerative Disc Disease Lumbar

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.